Suppr超能文献

巴德膀胱肿瘤抗原检测在监测有膀胱移行细胞癌病史患者中的结果。

Results of Bard BTA test in monitoring patients with a history of transitional cell cancer of the bladder.

作者信息

Ianari A, Sternberg C N, Rossetti A, Van Rijn A, Deidda A, Giannarelli D, Pansadoro V

机构信息

Fondazione Vincenzo Pansadoro, San Raffaele Scientific Institute, Rome, Italy.

出版信息

Urology. 1997 May;49(5):786-9. doi: 10.1016/S0090-4295(97)00081-2.

Abstract

OBJECTIVES

To evaluate the sensitivity and specificity of the Bard BTA test compared with bladder washing cytology in patients with a history of transitional cell bladder cancer undergoing routine follow-up cystoscopy.

METHODS

During routine follow-up for transitional cell bladder cancer, 75 patients underwent cystoscopy, bladder washing cytology, and the Bard BTA test, a latex agglutination test that qualitatively detects basement membrane complexes in voided urine. From October 1994 to October 1995, a total of 104 Bard BTA test examinations were performed. The results of the Bard BTA test were compared with those attained with cystoscopy and bladder washing cytology.

RESULTS

Cystoscopy found tumors in 13 cases. The Bard BTA test was diagnostic in 7 (54%) cases; it was more sensitive than bladder washing cytology, which was positive in only 3 (23%) cases. However, the specificity of the Bard BTA was lower (9% clinically unconfirmed positive tests) than that attained with cytology. In 2 patients (2%) in whom the cystoscopy was negative, the Bard BTA test was predictive for a positive cystoscopy 3 and 5 months later.

CONCLUSIONS

The Bard BTA test is a noninvasive test that may be an important addition to cystoscopy and cytology in the routine surveillance of patients with a history of transitional cell cancer of the bladder.

摘要

目的

在接受常规随访膀胱镜检查的移行细胞膀胱癌患者中,评估Bard BTA检测相较于膀胱冲洗细胞学检查的敏感性和特异性。

方法

在对移行细胞膀胱癌进行常规随访期间,75例患者接受了膀胱镜检查、膀胱冲洗细胞学检查以及Bard BTA检测(一种乳胶凝集试验,用于定性检测晨尿中的基底膜复合物)。从1994年10月至1995年10月,共进行了104次Bard BTA检测。将Bard BTA检测结果与膀胱镜检查和膀胱冲洗细胞学检查结果进行比较。

结果

膀胱镜检查发现13例肿瘤。Bard BTA检测在7例(54%)中具有诊断价值;它比膀胱冲洗细胞学检查更敏感,后者仅在3例(23%)中呈阳性。然而,Bard BTA的特异性低于细胞学检查(临床未确诊的阳性检测为9%)。在2例(2%)膀胱镜检查为阴性的患者中,Bard BTA检测预测3个月和5个月后膀胱镜检查呈阳性。

结论

Bard BTA检测是一种非侵入性检测,在对有膀胱移行细胞癌病史患者的常规监测中,可能是膀胱镜检查和细胞学检查的重要补充。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验